Journal of Translational and Practical Medicine regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Original Article
Treatment outcomes of our patients with prostate cancer who underwent postoperative radiotherapy
Aims: Prostate cancer is one of the most common cancers in men. Surgery, radiotherapy or active surveillance are the treatment options. Treatment is decided according to risk group of the patient. Postoperative radiotherapy is delivered in selected patients to increase the local control rates. The aim of this study is to report the treatment results of patients who received postoperative radiotherapy for localized prostate cancer.
Methods: This retrosepctive study included 78 prostate cancer patients who received postoperative radiotherapy between 2011 and 2023. All patients except who had pathologically positive lymph nodes were included into the study. Overall survival, progression free survival, and associated pathological parameters were evaluated by using IBM SPSS programme version 20.
Results: The mean follow-up time was 66.7 (IQR 25-75:41,6-89,6) months. Five and 10-year overall survival rates were 93%, and 67.3% respectively; (median (95% CI); NR (not reach): while 5 and 10-year progression-free survival rates were 90.3%, and 50.4, respectively; (median (95% CI); 135.3± (105.9-165.7). Postoperative prostate specific antigen (PSA) and pre-RT PSA values, and the effects of these parameters on progression-free survival was analyzed, median progression-free survival was higher in patients with postoperative PSA values ? 0.185 (135.6±24.4 vs 113.3±6.4, p:0.001). Five and 10 year overall survival and progression-free survival rates of patients with a high gleason score who underwent postoperative radiotherapy was observed lower than the others (86.9% and 46.3%, p=0.006; 86.9% and 33.8%, p=0.009 respectively).
Conclusion: Postoperative radiotherapy is generated best results in progression free survival and overall survival in patients with low pre-rt psa and high gleason score prostate cancer cases

1. Global Cancer Observatory: Cancer Today. 2020. . https://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-fact-sheet.pdf
2. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOGGuidelines on Prostate Cancer. Part 1: Screening, diagnosis, andlocal treatment with curative intent. Eur Urol. 2017;71(4):618-629. doi:10.1016/j.eururo.2016.08.003
3. Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patientswith recurrent prostate cancer after radical prostatectomy:prostate-specific antigen doubling time subgroups and theirassociated contributions to all-cause mortality. J Clin Oncol.2007;25(13):1765-71. doi:10.1200/jco.2006.08.0572
4. Viers BR, Sukov WR, Gettman MT, et al. Primary Gleasongrade 4 at the positive margin is associated with metastasisand death among patients with Gleason 7 prostate cancerundergoing radical prostatectomy. Eur Urol. 2014;66(6):1116-24.doi:10.1016/j.eururo.2014.07.004
5. Preisser F, Coxilha G, Heinze A, et al. Impact of positive surgicalmargin length and Gleason grade at the margin on biochemicalrecurrence in patients with organ-confined prostate cancer.Prostate. 2019;79(16):1832-1836. doi:10.1002/pros.23908
6. Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognosticvalue of biochemical recurrence following treatment withcurative intent for prostate cancer: a systematic review. Eur Urol.2019;75(6):967-987. doi:10.1016/j.eururo.2018.10.011
7. Thompson IM, Jr., Tangen CM, Paradelo J, et al. Adjuvantradiotherapy for pathologically advanced prostate cancer:a randomized clinical trial. JAMA. 2006;296(19):2329-35.doi:10.1001/jama.296.19.2329
8. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapyafter radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial22911). Lancet. 2012;380(9858):2018-27. doi:10.1016/s0140-6736(12)61253-7
9. Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapyversus wait-and-see after radical prostatectomy: 10-yearfollow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol.2014;66(2):243-50. doi:10.1016/j.eururo.2014.03.011
10. Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapyafter radical prostatectomy (RADICALS-RT): a randomised,controlled phase 3 trial. Lancet. 2020;396(10260):1413-1421.doi:10.1016/s0140-6736(20)31553-1
11. Kneebone A, Fraser-Browne C, Duchesne GM, et al. Adjuvantradiotherapy versus early salvage radiotherapy following radicalprostatectomy (TROG 08.03/ANZUP RAVES): a randomised,controlled, phase 3, non-inferiority trial. Lancet Oncol.2020;21(10):1331-1340. doi:10.1016/s1470-2045(20)30456-3
12. Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapyversus early salvage radiotherapy plus short-term androgendeprivation therapy in men with localised prostate cancer afterradical prostatectomy (GETUG-AFU 17): a randomised, phase3 trial. Lancet Oncol. 2020;21(10):1341-1352. doi:10.1016/s1470-2045(20)30454-x
13. Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvageradiotherapy for the treatment of localised and locally advancedprostate cancer: a prospectively planned systematic review andmeta-analysis of aggregate data. Lancet. 2020;396(10260):1422-1431. doi:10.1016/s0140-6736(20)31952-8
14. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specificsurvival following salvage radiotherapy vs observation in menwith biochemical recurrence after radical prostatectomy. JAMA.2008;299(23):2760-9. doi:10.1001/jama.299.23.2760
15. Hackman G, Taari K, Tammela TL, et al. Randomised trialof adjuvant radiotherapy following radical prostatectomyversus radical prostatectomy alone in prostate cancer patientswith positive margins or extracapsular extension. Eur Urol.2019;76(5):586-595. doi:10.1016/j.eururo.2019.07.001
16. Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapyfollowing radical prostatectomy. Eur Urol. 2014;65(6):1034-43.doi:10.1016/j.eururo.2013.08.013
17. Briganti A, Karnes RJ, Joniau S, et al. Prediction of outcomefollowing early salvage radiotherapy among patients withbiochemical recurrence after radical prostatectomy. Eur Urol.2014;66(3):479-86. doi:10.1016/j.eururo.2013.11.045
18. Chavaudra J, Bridier A. [Definition of volumes in externalradiotherapy: ICRU reports 50 and 62]. Cancer Radiother. Oct2001;5(5):472-8. Définition des volumes en radiothérapie externe:rapports ICRU 50 et 62. doi:10.1016/s1278-3218(01)00117-2
19. Croke J, Maclean J, Nyiri B, et al. Proposal of a post-prostatectomyclinical target volume based on pre-operative MRI: volumetricand dosimetric comparison to the RTOG guidelines. RadiatOncol. 2014;9:303. doi:10.1186/s13014-014-0303-6
20. Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can earlyimplementation of salvage radiotherapy for prostate cancerimprove the therapeutic ratio? A systematic review and regressionmeta-analysis with radiobiological modelling. Eur J Cancer.2012;48(6):837-44. doi:10.1016/j.ejca.2011.08.013
21. Tilki D, D'Amico AV. Timing of radiotherapy after radicalprostatectomy. Lancet. 2020;396(10260):1374-1375. doi:10.1016/s0140-6736(20)31957-7
22. Yoshida T, Nakayama M, Suzuki O, et al. Salvage radiotherapyfor prostate-specific antigen relapse after radical prostatectomyfor prostate cancer: a single-center experience. Jpn J Clin Oncol.2011;41(8):1031-6. doi:10.1093/jjco/hyr078
23. Miszczyk M, Majewski W, Stawiski K, et al. Prognostic factors inpostoperative radiotherapy for prostate cancer - tertiary centerexperience. Radiol Oncol. 2021;55(2):203-211. doi:10.2478/raon-2021-0017
Volume 2, Issue 2, 2023
Page : 41-45